Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Ultra Club
$500/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

HLS Therapeutics Inc. (T:HLS)

Business Focus: Retail - Drugs without Grocery

INK Edge Outlook

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for HLS within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 22, 2022 06:30 ET
HLS Therapeutics Obtains Public Reimbursement for Vascepa® in New Brunswick and with other Public Payors
New Brunswick, Northwest Territories and the Non-Insured Health Benefits (NIHB) program for First Nations and Inuit peoples will reimburse Vascepa for the reduction of cardiovascular risk in patients with established cardiovascular diseaseTORONTO, June 22, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focusing on central nervous system and cardiovascular markets, announces that it has successfully entered into Product Listing Agreements ("PLA") with New Brunswick, Northwest Territories and the NIHB, for the listing and public reimbursement o
Read full article
Jun 17, 2022 16:00 ET
HLS Therapeutics Reports Annual Meeting Results
TORONTO, June 17, 2022 /CNW/ - HLS Therapeutics Inc. ("HLS" or the "Company") (TSX: HLS), a pharmaceutical company focused on central nervous system and cardiovascular markets, announces voting results from its Annual Meeting of Shareholders held in a virtual format on June 17, 2022.
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
0.85
--
--
Price to Sales - TTM
5.02
2.54
5.75
Price to Book - most recent quarter
1.90
1.90
1.93
Price to Cash Flow per share - TTM
15.65
15.65
11.93
Price to Free Cash Flow per share - TTM
32.94
32.94
19.88
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 15, 2022113,34153,781
May 31, 202259,560-48,613
May 15, 2022108,173-48,500
See Short Report

Business Summary

Sector:  Consumer Non-Cyclicals Industry:  Drug Retailers

HLS Therapeutics Inc. is a Canada-based specialty pharmaceutical company. The Company is focused on developing clinically differentiated pharmaceutical products in the specialty central nervous system (CNS) and cardiovascular (CV) markets. Its products include Vascepa, Trinomia, Clozaril, CSAN Pronto, PERSERIS and MyCare Psychiatry/MyCare Insite. Its lead product, Clozaril, is an atypical antipsychotic indicated in the management of symptoms of treatment-resistant schizophrenia for the Canadian and United States markets. CSAN Pronto is a capillary point-of-care medical device designed to enhance and simplify the mandatory safety blood monitoring process for patients that are prescribed Clozaril. Vascepa capsules reduce the risk of cardiovascular events, such as cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, coronary revascularization, or hospitalization for unstable angina in statin-treated patients with elevated triglycerides.

See business summary

 

Twitter

Search (past week) for $HLS.CA

  • No tweets found